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Aryl iodides have become widely recognized as versatile synthetic
intermediates, owing to aromatic iodine’s excellent ability to participate in oxidative
addition reactions. Iodoarenes readily undergo a variety of synthetic transformations
including metal catalyzed cross-coupling reactions, diaryliodonium chemistry,
formation of organometallics through reduction or metal-halogen exchange, as well as
classical SN2 type chemistry. Because a wide array of transformations are available for
aryl iodides, organic molecules containing this moiety often serve as vital precursors
to highly desirable pharmaceuticals.
This thesis describes a simple and selective two-step approach to the formation
of aryl iodides. This method proceeds through an easily purified diaryliodonium salt
intermediate, which is subsequently converted to the corresponding aryl iodide. This
method is an effective and general process for the selective synthesis of a large variety
of monoiodinated arenes that are difficult to access by other approaches.
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CHAPTER ONE

POSITRON EMISSION TOMOGRAPHY

2
1.1

INTRODUCTION

1.1.1 Positron Emission Tomography
Positron Emission Tomography (PET) is a very powerful molecular imaging
technique that is used to produce a three dimensional image of certain organs within the
body. 1 This in vivo method allows for the non-invasive diagnosis of a wide range of
diseases, making it a useful tool in biomedical research. Through PET, researchers gain
valuable insight into vital physiological processes, which allows them to monitor the
pharmacokinetics and circulation of various drugs throughout the body. In order to
administer a PET scan, a drug labeled with a short-lived positron-emitting radioisotope is
prepared and injected into the body. These drugs are commonly referred to as
radiotracers. Once the radiotracer has become concentrated within the tissues or organs of
interest and cleared from background tissues, the patient is placed into a device known as
a scintillation detector (Figure 1.1).
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Figure 1.1 Diagram of a scintillation detector used in PET
The radionuclide of the labeled drug undergoes as process known as positive beta
decay, in which a positron is emitted. This positron travels a short distance, (about 2-5
mm) which is dependent upon the average kinetic energy of the ejected positron. When
the positron has lost enough energy to interact with an electron in the nearby tissues, an
annihilation event consumes both particles and produces a pair of 511 keV gamma rays
that radiate, at 180° angles, from the annihilation event. This coincident pair of photons is
then detected by the scintillation detector, which defines a line along which the
annihilation event occurred. Since the circular detector collects coincident events at many
angles, a map of the defined lines shows intersection points that pinpoint where, and in
what tissues, the radiotracer has become concentrated. The resolution of the image scales
inversely with the distance the positron travels before interacting with an electron in an
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annihilation event, and therefore radionuclides that emit positrons with low kinetic
energy yield the highest resolution images.

1.1.2 PET Imaging using Fluorine-18 (18F)
PET imaging has traditionally used radionuclides with relatively short half-lives,
such as carbon-11, nitrogen-13, oxygen-15, and fluorine-18. However, there are certain
considerations (Table 1.1) that must be taken into account when considering which
radioisotope to use, including the average positron kinetic energy, the specific activity,
and especially the half-life.

Table 1.1 Positron emitters commonly used in PET.

Isotope

Half-life

Decay mode

Eβ+Avg. (KeV)

Maximum
(Average)
Range in
Tissue (mm)

Maximum
Specific
Activity
(GBq/μmol)

11

C

20.39 min

β+ (99.8%)
EC (0.24%)

385

3.8 (1)

3.4x105

13

N

9.965 min

β+ (99.8%)
EC (0.2%)

491

5 (1.5)

7.0x105

18

O

122.24 sec

β+ (99.9%)
EC (0.1%)

735

7.6 (2.7)

3.4x106

18

F

109.77 min

β+ (96.73%)
EC (3.3%)

242

2.2 (0.3)

6.3x104

4.1760 days

β+ (22.8%)
EC (11.0%), e-

188

9.7 (3)

1.2x103

124

I

Nuclear properties of commonly used positron emitting radionuclides used in PET. Data taken from
Brown and Firestone 1986 and from Brookhaven National Laboratory internet database, BNL 2003

18

F-labeled imaging agents provide higher resolution images that those afforded

by tracers labeled with the other radionuclides listed in Table 1.1. The reason for this is
that 18F emits a positron with relatively low kinetic energy, which is associated with an
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annihilation event closer to the decay event. A short half-life is desirable for most
diagnostic scans involving small molecule tracers that localize and clear quickly, but the
synthetic routes used to synthesize many radiotracers preclude all but the most wellequipped hospitals from using novel PET diagnostic agents.

Generally, a nearby

cyclotron and an experimental radiochemistry laboratory are required in order to
synthesize 18F-labeled radiotracers. It is more common for hospitals to purchase standard
18

F-labeled

tracers,

such

as

fluorodeoxyglucose

(FDG),

from

commercial

radiopharmacies.
Generally, one desires a radiotracer to have the shortest possible half-life that is
commensurate with obtaining a quality image. In practice this means that the
radionuclide half-life must be sufficiently long to allow for synthesis of the radiotracer
from the radionuclide, administration to the patient, localization in the tissue of interest,
and clearance from background tissue. Toward these ends, fluorine-18 is the most
commonly used radionuclide for incorporation into small molecule radiotracers,2 as it can
be synthesized off-site, incorporated into a radiotracer, and then shipped to diagnostic
centers while still retaining a useful amount of radioactivity. In addition, the nuclear
reaction which produces

18

F from H218O yields several hundred times the amount of

18

F

needed for a single human PET scan, and synthetic routes exist that give desirable
radiotracers in high radiochemical yields.3
Choosing to use

18

F as the radiolabel on pharmaceutical provides additional

benefits to those outlined above. 4 The carbon-fluorine bond is one of the strongest in
organic chemistry, owing to fluorine’s high electronegativity. The dipolar nature of the
C-F bond induces an electrostatic attraction between carbon and fluorine,5 which shortens
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and strengthens the bond. Replacing hydrogen atoms with fluorine in pharmaceuticals6
also lends metabolic stability to the carbon framework, while introducing minimal
structural perturbations. The small size of the fluorine atom makes it an appropriate
replacement for hydrogen, thus, singly fluorinated organic compounds often behave very
similarly to the corresponding hydrocarbon. While replacing hydrogen with fluorine in
organic compounds changes little in the way of the physical structure of the compound,
the fluorine is highly electronegative and alters the electronic properties of the
molecule,7,8 making it a good bioisostere for a Lewis basic hydroxyl group.

Figure 1.2 Common 18F and F labeled pharmaceuticals. Figure adapted from reference 90.
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Because of these advantages, about one fifth of all pharmaceuticals contain at
least one fluorine atom. Incorporation of fluorine into pharmaceuticals has been reported
to increase the likelihood of creating a successful drug by a factor of ten9,10 (Figure 1.2).
Fluorine substituted organic compounds often display increased lipophilicity over their
corresponding hydrocarbons, which can be a desirable pharmacological property in some
cases.11 Additionally, replacing hydrogen with fluorine at a site of metabolic oxidation
may extend the serum half-live of a drug in the body. This is an especially useful strategy
to protect drugs that are susceptible to cytochrome P-450 catalyzed hydroxylation, a
catabolic process that accounts for approximately 75% of all drug metabolites.
Replacement of an aromatic hydrogen with fluorine stabilizes aromatic groups that are
sensitive to this type of drug metabolism.12-18
1.1.3 Routes to 18F-labeled Radiotracers
While

18

F is a highly desirable radiolabel, the introduction of

18

F into

pharmaceuticals poses a significant challenge for organic chemists. Elemental fluorine
and hydrogen fluoride are difficult to handle and require specialized techniques and
equipment, as they are highly reactive and very dangerous. Fluorine is one of the most
reactive substances known, due to the strength of the bonds that fluorine forms with most
other elements and the relative weakness of the fluorine-fluorine bond.
In order to accomplish the difficult task of fluorination, a variety of methods may
be used. Electrophilic fluorination is a common method employed, and for this purpose
elemental fluorine is commonly used in the form [18F]F2. Radioactive fluorine [18F]F2
used in electrophilic labeling techniques is generated in a cyclotron. The most common
nuclear reaction used is 18O(p,n)18F in which the bombardment of [18O]-oxygen produces
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[18F]F2, although a different, less common, reaction,

20

Ne(d,α)18F uses neon as the

bombardment target. In the reaction using [18O]-oxygen, a trace amount of F2 gas is
sometimes added to extract the radioactive [18F]F2, which produces a mixture of [18F]F2
and [19F]F2 as the final product. This method is called “carrier added.” In practice, only a
handful of cyclotron facilities in the world are able to produce [18F]F2 on a reliable basis.
When using elemental fluorine, the fluorine molecule is highly polarized, which
allows electron-rich or Lewis basic substrates to act as nucleophiles. If this method is
utilized, the upper limit of the radiochemical yield (RCY) is only 50%, due to the fact
that 50% of the radioactivity is consumed in the chemical transformation and the other
50% is lost as the leaving group.2 Electrophilic fluorination with F2 also suffers from low
specific activity of the final product, because a carrier gas (non-radioactive F2) is added
in order to extract the [18F]F2. Due to these limitations, the electrophilic fluorination
method is only commonly used in applications that don’t require a radiotracer with a high
specific activity. When a higher specific activity product is necessary and electrophilic
fluorination is the desired synthetic route, other fluorination reagents such as xenon
difluoride, N-fluorinated amines, amides, and sulfonamides are used.2 Because the source
of electrophilic fluorine is contained within the reagent itself, instead of within diatomic
fluorine (where one atom of radioactive fluorine is consumed in the transformation and
the other half is converted to unusable radioactive fluoride) these reagents are able to
provide a higher specific activity material.
The method used to obtain [18F]-fluoride for use in nucleophilic labeling reactions
(18O(p,n)18F) is similar to the reaction used to produce [18F]F2, except that the product is
obtained as [18F]HF from an [18O]-H2O target. This solution is then passed through an
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ion-exchange resin, which traps the [18F]-fluoride. A solution containing K2CO3 and
kryptofix 2.2.2 (Figure 1.3) is then used to elute radioactive fluoride (as [18F]KF) from
the ion-exchange resin into a reactor vial. Typically, the reagent is then mixed with
acetonitrile and subject to azeotropic distillations to remove excess water to prepare a
highly nucleophilic form of fluoride.2

Figure 1.3 Kryptofix™ 2.2.2
Nucleophilic methods have been used to radiofluorinate a variety of compounds.
These no carrier added (nca) nucleophilic methods, in which the cyclotron produced
[18F]F- is used directly, can result in very high specific activity products ( > 4 x 103 GBq
μmol-1). Certain challenges are apparent if fluoride is to be used in nucleophile reaction,
as fluoride is generally considered to be a poor nucleophile. However, fluoride is a
moderate nucleophile, but only when it is desolvated, so every effort is made to eliminate
potentially hydrogen bonding impurities (like water) to enhance the rates of reaction.
Since alkyl fluorides are highly stable compounds, quite aggressive reaction conditions
can generally be used for SN2 reactions to form alkyl fluorides.
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Regardless of whether an electrophilic or nucleophilic method of fluorination is
used, there are certain constraints placed upon the method of synthesizing the radiotracer,
due to the inherent properties of

18

F. The relatively short-half life of 18F makes it

desirable to minimize the number of post-labeling synthetic transformations as well as the
length of any necessary purification processes. While many carrier added electrophilic
fluorination methodologies seem attractive in this regard, they suffer from low selectivity
during the labeling step, which translates into a low specific activity final product.
Because high specific activity product is often required in imaging applications,
radiochemists are often willing to use multistep syntheses and complex protecting group
strategies so that [18F]-fluoride may be used to generate high specific activity products.
Some of the most desirable radiotracers contain fluoroarenes. Radiotracers
incorporated onto electron-poor arenes may be synthesized using classical SNAr reactions
such as halogen exchange or fluorodenitration reactions. Strategies to prepare
radiotracers that possess [18F]-fluorinated electron-rich aromatic groups include direct
fluorination with [18F]F2 or electrophilic reagents derived from [18F]F2, or, more
commonly fluorodestannylation. As outlined above, electrophilic methods generally
provide tracers that have low specific activity. Due to this limitation, a method that is
fast, high yielding, and highly selective, while affording the ability to radiolabel both
activated and deactivated substrates using a no carrier added nucleophilic [18F]F- is highly
desirable. One objective of research in the DiMagno group is to provide a solution to this
general problem.
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1.1.4 Typical Aromatic Fluorination Methods
One very simple and straightforward method of obtaining aryl fluorides is to
employ a SNAr reaction to displace a leaving group with fluoride. These types of
reactions often require high boiling solvents and high temperatures, which may not be
compatible with sensitive functional groups. Also, owing to the miniscule amount of
[18F]F- present under no carrier added conditions (< 10 ng), a large excess of the desired
halogenated arene precursor is required to drive the reaction to completion. For
radiotracer synthesis, the SNAr approach can lead to significant purification problems.
One of the most well-known reactions used to produce fluoroarenes is the BalzSchiemann (Sandmeyer) reaction. In this method, anilines are converted to diazonium
fluoroborates, which are subsequently converted to aryl fluorides (Scheme 1.1). This
route has been used to produce several 18F labeled radiotracers, including [18F]-F-DOPA,
although the RCY suffers as a result of the use of BF4-, which limits the maximum
radiochemical yield to only 25% since only one

18

F contained within the BF4- anion is

transferred to the arene.2 This method is also not tolerant to many acid-labile functional
or protecting groups that may need to be used in the synthetic strategy, and as a result,
fluoroborates are not generally used as a radiosynthetic strategy.2

Scheme 1.1 Balz-Schiemann reaction.
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Another method that has been developed to fluorinate electron-rich aromatic
compounds is based upon palladium-catalyzed cross coupling reaction, a strategy first
developed by Buchwald (Scheme 1.2). A solution to this long-standing problem was
noteworthy, because one would expect that the strength of the Pd-F bond would lead to
relatively high barriers to reductive elimination of Pd0 to form the fluoroarene during the
last catalytic step. However, this method is most effective when deactivated aromatics are
the labeling target, as more electron rich compounds require a large excess of the
fluorination reagent (6 equivalents of CsF), higher temperatures and longer reaction times
(12 hours). This method suffers from less than perfect regioselectivity, and the toxicity of
heavy metals is also a concern, as any potential pharmaceutical must remain metal-free,
which limits its use as a synthetic strategy to obtain 18F radiolabeled drugs.19-23

Scheme 1.2 Pd-catalyzed aromatic fluorination.
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1.1.5 Diaryliodonium Salts as Precursors to Aryl Fluorides
In organometallic metal chemistry, it is well known that high-valent and/or
electronegative transition metal ions are more prone to reductive elimination.20 Using
recent developments in palladium-catalyzed cross coupling reactions as an analogy, it
was postulated that iodine should behave like a high-valent, highly electronegative
transition metal ion in reductive elimination reactions. In addition, because the bond
between fluorine and palladium is stronger than the bond between fluorine and iodine,
reductive elimination reactions at I(III) centers should occur more readily than reductive
elimination reactions at Pd(II) centers. Furthermore, Ar2M(X)n complexes usually give
biaryl compounds upon reductive elimination, whereas Ar2IX compounds generally from
Ar-I and Ar-F compounds upon reductive elimination. Because of these properties, our
group has explored reductive elimination reactions from I(III) centers to develop a
potentially more facile route to fluoroarenes (Figure 1.4).
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Figure 1.4 Iodine used as a transition metal.

The decomposition of diaryliodonium salts (IUPAC: diaryl-λ3-iodanes) to aryl
halides is a reaction that has been known for over one hundred years, but only recently
has this type of chemistry come into the spotlight.88 The current popularity of
diaryliodonium chemistry in radiochemistry circles is due to the ability of this class of
salts to rapidly undergo reductive elimination to form aryl fluorides.24-27 This property
grants them special utility as radiotracer precursors. In most cases, the desired radiotracer
can be obtained in one “hot” step after the desired diaryliodane is in hand. Developing
especially high yielding radiolabeling strategies using this particular class of compounds
is a primary focus of research in the DiMagno group.
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Scheme 1.3 Common strategies used to synthesize I(III) compounds.

A variety of methods allow one to synthesize iodonium salts from relatively
simple arenes. However, in order for synthetic methods to be relevant to radiotracer
synthesis, they must be general, have high functional group tolerance, and be compatible
with any needed acid-labile protecting groups. (Nucleophilic radiofluorination reactions
are generally performed with excess base present.) Two common strategies (Scheme 1.3)
utilize oxidizing agents in the presence of acid, which would disqualify any drug
containing acid-labile groups from being a candidate for diaryliodonium salt formation. A
new strategy (Scheme 1.4), derived from the work of Shreeve,89 circumvents this
limitation by using the mild oxidant Selectfluor™ in the presence of TMS-acetate to give
the diacetate in high yield under neutral conditions. Importantly, this process leaves acidlabile protecting groups intact.
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Scheme 1.4 Different methods used to synthesize I(III) compounds.

There are numerous literature examples describing the preparation of aryl
fluorides from diaryliodonium salts. It has been suggested that the decomposition of
diaryl-λ3-iodanes proceeds via an SNAr mechanism, which directs the nucleophilic
fluoride onto the ipso carbon of the less electron rich arene due to the ability of the
electron poor ring to stabilize the negative charge that develops in the transition state.87
Because of this, many diaryliodonium salts employ electron rich arenes such as 4iodoanisole and 2-thienyl as the opposing arene.28-30 Because fluorination of
diaryliodonium salts involves ionic reactants, this reaction was performed exclusively in
polar media previously. However, work in our laboratory has shown that the use of
nonpolar solvents, such as benzene or toluene, suppress detrimental side reactions and
permit aryl fluorides to be prepared in greater yield.
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With the ability to quickly synthesize a wide variety of diaryliodonium salts in
high yield, and the capability to quickly and cleanly obtain the corresponding radiotracers
from these compounds, my focus shifted to expanding the scope of the diaryliodonium
salt method. In order to arrive at diaryliodonium salt precursors, however, it was
necessary to develop a more general and selective method to iodinate compounds that
would be later transformed into radiotracer precursors.
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CHAPTER TWO

IODINATED COMPOUNDS IN RADIOSYNTHESIS
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2.1

BACKGROUND

2.1.1 Aromatic Iodination
Aryl iodides have become widely recognized as versatile synthetic intermediates,
owing to iodine’s excellent ability to act as a leaving group. Iodoarenes readily undergo a
variety of synthetic transformations including metal-catalyzed cross-coupling reactions,
diaryliodonium salt chemistry, Grignard reactions, as well as classical SNAr type
chemistry. Because a wide array of transformations are available for aryl iodides, organic
molecules containing this moiety often serve as vital precursors to highly desirable
pharmaceuticals.
The wide array of methods that have been developed for iodoarene synthesis
serves as evidence that the fabrication of these important pharmaceutical precursors is not
straightforward, and that the reaction conditions must be carefully tuned to match the
substrate. This complication arises from the fact that elemental iodine is the weakest
electrophile of the halogens, and as a result, synthetic routes to aryl iodides often require
harsh reaction conditions and highly activated reagents. Moreover, iodine is a relatively
weak electron-withdrawing aryl substituent63 (Hammett σp = 0.18, σm = 0.35, σ+ = 0.14),
so polyiodination is often a problem when very electron rich substrates or highly
activated reagents are used. Activated substrates readily undergo electrophilic iodination,
although often with poor selectivity. However, deactivated arenes are often difficult to
iodinate, requiring powerful oxidants and long reaction times in concentrated acid. These
problems limit the accessibility of iodinated intermediates as pharmaceutical precursors.
To arrive at these versatile iodoarene intermediates from the corresponding
aromatic compounds, a variety of reagents may be used, including N-iodosuccinimide
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(NIS), iodine monochloride (ICl), sodium iodide or molecular iodine used in combination
with a variety of oxidants, bis(pyridine)-iodonium(I) tetrafluroborate (Py2IBF4), and
silver or mercury salts combined with I2 (Scheme 2.1). Iodoarenes may also be
synthesized by various substitution reactions from compounds such as aryl amines, aryl
halides, aryl boronic acids, aryl triflates and aryl silanes.31-61

Ar H
Ar H

Ar H

KI NaIO4

Ar

I

Ag2SO4

ICl

IS
(O
Ac
)2
I2

Ar H

AgTFA

I 2 c) 4
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"I +
nB "
uL
i

H2SO4

Ar H

N

Pd

TM

I2
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ﬂu
ct
le
Se

NIS
TFA

Ar H

Ar H

Ar H

Scheme 2.1 Various reactions used to synthesize aryl iodides.

Recently, a literature review describing various electrophilic aromatic iodination
procedures was published.64 Despite the range of reagent systems described in the review,
there remains the need for a versatile, straightforward, and highly selective aromatic
iodination method. For example, even the iodination of benzene is not straightforward; a
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wide variety of the methods used failed to produce iodobenzene in quantitative yield
(Table 1.2). The notable exception was molecular iodine and silver triflate in
dichloromethane, however, for the purposes of pharmaceutical synthesis, this reaction is
problematic.
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Table 2.1 Iodination of benzene.

Entry

Reagent

Conditions

Temp (ºC)

Yield (%)

Reference

1

I2, CrO3

AcOH, Ac2O, H2SO4

65

76

65

2

I2, SPCa

AcOH, Ac2O, H2SO4

40

40

66

3

I2, I2O5

AcOH, H2SO4

60

56

67

4

I2/KI, PVPb-H2O2

H3PW12O40, (cat.), CH2Cl2

reflux

15-22

68

5

I2/NaI, Fe(NO3)3•N2O4

CH2Cl2

r.t.

74

69

6

NaI, Ce(OH)3OOH

aq. SDS

r.t.

80

70

7

KI, KBrO3, H+

60% AcOH/HCl

80

91

71

8

I2, XeF2

CH2Cl2

r.t.

90

72

9

I2, Hg(NO3)2

CH2Cl2

r.t.

52

73

10

I2, AgOTf

CH2Cl2

r.t.

100

74

*Data drawn from from reference 64.
a
SPC = Sodium percarbonate
b
PVP = polyvinylpyrrolidone

The results obtained from the iodination of alkylbenzenes are similarly
disappointing. Toluene iodination ordinarily yields a mixture of 2- and 4-iodotoluene in
systems using relatively harsh reaction conditions. Greater than average selectivity can be
obtained under milder conditions at longer reaction times or in reactions that employ
metal catalysts such as tungsten or vanadium (Table 1.3).
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Table 2.2 Iodination of toluene.

Entry

Reagent

Conditions

Temp (ºC)

Ratio (o:p)

Yield (%)

Reference

1

NaI or KI

Oleum

60-120

0:100

76

75

2

I2, AgOTf

CH2Cl2

r.t.

25:75

100

74

3

I2, Hg(NO3)2

CH2Cl2

r.t.

35:65

92

73

4

I2, Fe(NO3)3

CH2Cl2a

20

0:100

59

76

5

I2, Fe(NO3)3•N2O4

CH2Cl2

r.t.

40:60

93

69

6

NaI, Ce(OH)3OOH

aq. SDS

r.t.

0:100

87

70

7

I2, H5IO6

EtOH

60

8:92

44

77

8

I2, F-TEDA-BF4

[bmim][PF6]

80

35:65

40

78

9

I2, O2

MeCNb

80

15:85

99

79

*Data drawn from from reference 64.
a
Catalytic H3PW12O40
b
H5PV2Mo10O40

In cases where the iodination of polysubstituted alkylbenzene derivatives was
attempted, regioisomers and multiple iodination were observed in all but the most
specific cases. This lack of selectivity is especially troublesome when attempting to
iodinate compounds for which the sums of the substituent Hammett sigma values are
similar. Furthermore, because the iodine substituent is not particularly deactivating,
compounds that have already undergone iodination are susceptible to further iodination.
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Scheme 2.2 Sandmeyer synthesis of iodoarenes.

Iodination of relatively electron-poor arenes is a difficult task, conventionally
accomplished by the indirect approach using the Sandmeyer reaction80-82 (Scheme 1.6).
The alternatives to the Sandmeyer reaction discussed within this section commonly
employ harsh reaction conditions, use a large excess of the iodination reagent,
concentrated acid, high temperatures and long reaction times, and/or strong oxidants in
order to complete the transformation.84-86 Under these conditions, it is difficult to prevent
multiple iodination, especially if there are two nearly equivalent positions at which
iodination may occur. In addition, these harsh reaction conditions are often not
compatible with functional or protective groups that may be necessary for the synthesis
of complex pharmaceutical candidates.

2.1.2 Aromatic Iodination via Diaryliodonium Salt Decomposition
Because of the difficulty encountered during the iodination of both electron-rich
and electron-poor aromatics, we sought a new method that would be selective and robust
enough that the method could be used to iodinate a wide variety of aromatic substrates. In
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order to solve this problem, we turned our attention once again to diaryliodonium
chemistry.
In order to iodinate any given compound using iodane chemistry, the compound
in question must first necessarily be transformed into the corresponding diaryliodonium
salt. This procedure is not trivial, and introduces one or more additional steps into the
reaction sequence. Typical procedures for preparing diaryliodonium salts involve
electrophilic and nucleophilic partners, which condense to form the diaryliodonium salt.
Naturally, this rather complex approach would require an arene already functionalized in
the appropriate position, and would be a nonsensical method to prepare standard iodides.
One such approach is shown in (Scheme 1.7).

Scheme 2.3 Synthesis of diaryliodonium salts.

A second issue is that the thermal decomposition of diaryliodonium salts leads to
the formation of two different iodides (if X = I in Figure 1.5), thus there could be a
separations problem if the two iodoarenes are chemically similar.
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Figure 2.1 Products resulting from the reductive elimination of a diaryliodonium salt.

In summary, there are two main problems encountered when attempting to use
iodane chemistry to introduce iodine into a pharmaceutical precursor. First, the typical
methods used to obtain the necessary diaryliodonium salts employ precursors that could
provide the aryl iodides directly; and second, the decomposition of the resulting
iodonium salt step may give a mixture of products, which could require further costly and
time-consuming purification steps.83-84 In the following section, I present a fairly general
solution to the arene iodination problem, and show that it can be applied to a wide range
of substrates.

2.2

RESULTS AND DISCUSSION
Portions of the rest of this section are drawn from a journal article on which I am

a coauthor. Direct quotations are indicated with quotation marks. I have clearly attributed
individual contributions.
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In order to overcome the problems outlined previously, I developed a selective
iodination methodology that can be used to functionalize a variety of electronically
deactivated to activated arenes.
In order to address the problem of multiple iodine additions for compounds that
contain several positions susceptible to electrophilic aromatic substitution, we developed
a strategy that exploits a fundamental property of I(III) chemistry: the aryliodonium
substituent is very electron withdrawing (σp = 1.37, σm = 1.35 for PhI(BF4). To put this in
context, the corresponding values for the nitro substituent are: σp = 0.79, σm = 0.71. Thus,
any method that involves electrophilic substitution to form an Ar-I(III) intermediate
effectively eliminates the possibility of any further electrophilic substitution by an “I+”
species (Scheme 1.8)

Scheme 2.4 Resistance of diaryliodonium salts to further EAS

With this strategy in hand, I turned my attention toward developing a direct
electrophilic substitution method that could be used with a variety of arenes. With my
attention focused on developing a “one step addition” route to diaryliodonium salts, I
envisioned a diacetoxyiodoarene that would be sufficiently electron-poor so that the I(III)
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moiety would readily undergo electrophilic aromatic substitution with the desired
substrates. To this end, I devised two reagents containing substituents of a sufficiently
electron-withdrawing nature to facilitate the EAS reaction between arenes and the I(III)
center of a diacetoxyiodoarene (Scheme 1.9).

Scheme 2.5 Reagents used for “One Step Addition”

Reagent

1

((4-nitrophenyl)iodonium

diacetate)

and

reagent

2

((3,5-

dicarboxymethylphenyl)iodonium diacetate), were obtained in good yield by treating the
corresponding iodides with 1.3 equivalents of Selectfluor™ and 2.6 equivalents of
TMSOAc in acetonitrile (Scheme 1.10). These compounds are stable materials, and they
are unreactive toward standard arenes in acetonitrile at room temperature.
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Scheme 2.6 Synthesis of aryliodonium diacetates

Upon electrophilic activation of 1 or 2 with trimethylsilyl triflate (TMSOTf),
ligand exchange occurs and several different I(III) species (ArI(OAc)2, ArI(OAc)(OTf),
and ArI(OTf)2) are observed. The evidence for this equilibration can be seen in the
downfield shifts of signals in the aromatic region of the 1H NMR spectrum, and by a
signal consistent with generation of TMSOAc. The greater electrophilicity of the I(III)
center, which is suggested by the downfield shifts of the signals in the 1H NMR spectrum
following treatment of ArI(OAc)2 with TMSOTf, was confirmed when an arene such as
toluene was added; the activated reagents participated in an EAS reaction to give the
corresponding diaryliodonium salt at room temperature (Scheme 2.7).
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Scheme 2.7 Activation of the aryliodination reagent and reaction with toluene.

With the diaryliodonium triflate in hand, the corresponding aryl iodide can be
formed quickly and simply by treatment with tetramethylammonium iodide (TMAI) and
heating (Scheme 2.8).

Scheme 2.8 Conversion of the diaryliodonium triflate to the iodoarene.

In order to determine the general scope of the reaction, I performed a comparison
between traditional iodination strategies employing the use of N-iodosuccinimide (NIS)
and Selectfluor™ and our methodology, which employs an I(III) substituted arene. For
Method A and B, one and two equivalents of NIS were used to assess the selectivity and
to attempt to drive the reaction to completion, respectively. Likewise, for Method C and
D, one half and one equivalent of Selectfluor™ and I2 were used for similar purposes.
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For Method E, two equivalents of the aryliodination reagent 1 or 2 and four
equivalents of trimethylsilyl triflate (TMSOTf) were used to ensure that all of the arene
was consumed, and to ensure that multiple iodination did not occur. Because this was a
preliminary survey of reactivity and scope, and because the decomposition of
diaryliodonium salts is a thoroughly investigated topic and has been known for over a
century, the yields listed column E refer only to the yields of the diaryliodonium salt
intermediate. Even so, the results shown in Table 1.4 indicate that for a wide range of
substrates, the aryliodination strategy promises to be superior in many regards.
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Table 2.3. Comparison between standard iodination strategies and the diaryliodination
strategy. For column E, I = I(OTf)(Ph(NO2)).
Method & Yielda,b (%)
Entry
Reactant
Product(s)
A
B
C
D
Ec

1

78.1 79.7

69.4

26.7

>99c

0

0

16.0

57.2

0

0

0

4.2

16.1

0

63.7 100

100

50.7

>99c

0

0

0

49.7

0

100

43.0

95.8

3.4

>99c

0

57.0

1.6

96.6

0

100

100

100

100

>99

3

2
4

3
5

4
6
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Entry

Reactant

Product(s)

A

Method & Yielda,b (%)
B
C
D
Ec

-

62.0

85.1

0

>99

-

38.0

14.9

100

0

80.6 100

100

100

>99

23.6 36.3

65.2

77.8

>99

4.1

6.5

21.4

0

74.6 74.5

64.1

9.7

88

16.4 12.4

13.4

0

12

0

10.2

17.6

74.6

0

0

2.9

4.9

15.7

0

5
7

6
8

7
9

5.6

8
10
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Entry

Reactant

9

Product(s)

A

Method & Yielda,b (%)
B
C
D
Ec

22.5 35.3

76.1

84.3

>99

30.8 55.2

76.9

100

>99

34.6 88.5

88.0

94.5

19.9 23.2

41.2

45.0

90c

21.5 20.9

44.5

48.6

10

0

0

6.3

0

64.1 82.1

90.7

45.1

>99c

1.3

2.5

7.3

51.0

0

0

0

1.8

3.8

0

11
10
12
12
13

11
14

12

0

15

35

Entry

Reactant

13

Product(s)

A

Method & Yielda,b (%)
B
C
D
Ec

24.8 19.8

66.6

81

>99

16
a

Yield determined by 1H NMR, Full descriptions of methods A-F can be found in Appendix X
b
Method A: 1.1 eq. NIS/TFA
Method B: 2.2 eq. NIS/TFA
Method C: 0.5 eq. Selectfluor™/I2
Method D: 1.1 eq. Selectfluor™/I2
Method E: 2.0 eq. 1 (Nitrophenyliodonium diacetate) & 4.0 eq TMSOTf
Method E: 2.0 eq. 2 (3,5-dicarboxymethyl)phenyliodonium diacetate & 4.0 eq TMSOTf
c
Yield of diaryliodonium salt intermediate

For all of the alkyl substituted benzenes except toluene and 3-bromoanisole, the
aryliodination strategy proceeded to 100% conversion within a 2 hours, and produced
only a single regioisomer, while the N-iodosuccinimide and Selectfluor™ iodination
method required overnight heating, and gave multiple regioisomers or multiply iodinated
products.
Of special note is the comparison of the iodination of p-xylene. When treated with
one equivalent of N-iodosuccinimide, only 64% of the monoiodination product was
observed, accompanied by 1.5% of the doubly iodinated product. When subjected to 2
equivalents of N-iodosuccinimide, the reaction did not proceed to completion, but yielded
only 82% of the desired mono-iodinated product, while also giving nearly 3% of the
doubly-iodinated product. However, when p-xylene was treated with 2 equivalents of the
aryliodination reagent 2, the reaction proceeded to completion within one hour at room
temperature, and gave the desired product in 99% yield. Similar results are observed for a
wide range of molecules.
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The aryliodination was also shown to be applicable to substrates ranging from
benzaldehydes (electronically deactivated) to anilines (highly activated). In all cases
where the aryliodination reagent was used, the starting material was completely
consumed, regardless of electron-rich or poorness. This wide range of reactivity makes
this iodination strategy particularly attractive as a robust, highly versatile alternative to
other methods.
However, there are several drawbacks to the aryliodination approach. “The
presence of free N-H bonds and phenolic hydroxyl groups were incompatible with the
aryliodination reaction, although simple protecting group strategies should provide a
workaround to this problem. Importantly, the presence of hydrogen bonding groups in the
absence of a reducing functional group is tolerated. Highly reducing arenes (1,4dimethylaminobenzene, 1,4-dimethoxybenzene) participated in redox reactions rather
than EAS, indicating that reduction of the aryliodonium salt was the principal side
reaction that limits the utility of this method.” For the iodination of particularly electronrich aromatics, it is probable that a less activated aryliodonium reagent may be used. In
these cases, it is likely that the reaction may be modified to suit these electron-rich
substrates by simply using less potent activator such as trimethylsilyl trifluoroacetate
(TMSTFA) or similar TMS-X reagent.
In order to determine the optimal conditions for the reaction, Bao Hu, a
postdoctoral fellow in the DiMagno laboratory, surveyed the amounts of the
aryliodination reagent and TMSOTf needed to generate the active electrophile in
deuterated acetonitrile (CD3CN). The activated aryliodonium species, prepared under a
variety of conditions, was treated with one equivalent of toluene at room temperature.
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Under the optimized conditions (Table 1.4), conversion of arene to the diaryliodonium
salt was complete within one hour. Subsequent treatment with an excess (3 equivalents)
of sodium iodide and heat (80º C) was sufficient to convert the diaryliodonium salt to the
corresponding aryl iodides. Excess iodide was used for two reasons: it pushes the
equilibrium for the intermediate diaryliodonium triflate to the iodide, and it also
eliminates any unreacted ArIX2 reagent remaining upon completion of the reaction by
reduction (2I-  I2).

Table 2.4 Optimization conditions for aryliodination

Entry

Reagent

Ratiob

t (h)

conv. (%)c

Iodide
source

eq.

T (°C)

t (h)

conv. (%)d

1

1

1.0/1.5/1.5

1

66

–

–

–

–

–

2

1

1.0/1.5/1.5

8

98

TMAI

2.0

80

13

68

3

1

1.0/2.0/4.0

0.5

95

–

–

–

–

–

4

1

1.0/2.0/4.0

1

>99

TMAI

2.0

120

1

46

5

1

1.0/1.5/3.0

1

>99

TMAI

2.0

120

1

71

6

1

1.0/1.5/3.0

1

>99

TMAI

2.0

120

4

95

7

1

1.0/1.5/3.0

1

>99

TMAI

4.0

80

1

>99

8

1

1.0/1.5/3.0

1

>99

TMAI

3.0

80

1

>99
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a

91b

1

1.0/1.5/3.0

1

>99

TBAI

3.0

80

1

>99

10

1

1.0/1.5/3.0

1

>99

NaI

3.0

80

1

>99 (>95)e

11

2

1.0/1.5/1.5

1

30

–

–

–

–

–

12

2

1.0/1.5/1.5

29

97

–

–

–

–

–

13

2

1.0/1.5/3.0

1

>99

NaI

3.0

120

22

>99 (>95)e

Reaction conditions: 0.10 mmol scale, 1.5 mL of CD3CN, N2.

b

Toluene/1 (or 2)/TMSOTf.

c

Based on toluene. dBased on 4.

e

Yields were determined by 1H NMR spectroscopy.

The mild (room temperature, no strong oxidant or protic acid) conditions under
which this reaction takes place suggest that the I(III) electrophile is quite potent, yet the
reaction proceeds with good regioselectivity. The 9:1 ratio of 4-iodotoluene to 2iodotoluene indicates that the regioselectivity observed in the original diaryliodonium salt
formation is carried through to the products during the decomposition step.
With the optimized reaction conditions in hand, Dr. Hu sought to further illustrate
the benefits of using the diaryliodonium method of iodination in comparison to more
common procedures. As a starting point, and because the aryliodination methodology
proceeds quite mildly at room temperature, several common iodination strategies were
performed on toluene at room temperature. These results are shown in Scheme 1.12.
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Scheme 2.9 Comparison of toluene iodination.

Dr. Hu also performed a survey of the scope of the reaction for the decomposition
of the diaryliodonium intermediate. For most of the arenes surveyed, the reaction
proceeded to more than 99% conversion to the diaryliodonium intermediate within one
hour at room temperature when 1.5 equivalents of the aryliodination reagent (1 or 2) and
3 equivalents of TMSOTf were used. The diaryliodonium intermediate was converted
rapidly (within 1 hour) to the corresponding iodide when treated with 3 equivalents of
sodium iodide in acetonitrile at 80º C. These results are compiled in Table 1.6. In no case
were multiply iodinated products observed.

40
Table 2.5 Survey of the scope of the aryliodination reaction.

Entry

Arene

Yield (%)b

Product

1

86c

2

75d

3

4

5

6

78
98e
84e,f

93

>95

79
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Entry

7

8

9

Arene

Product

Yield (%)b

>95

84g

>95g
>95e,g,h
81e,g,h,i

a

Reaction conditions: 0.10 mmol scale, arene/1/TMSOTf/NaI = 1:1.5:1.5:3.0, 1.5 mL of CD3CN, N2.
For details of operation, see the Supporting Information.
b
Determined by 1H NMR using an internal std.
c
The iodination required 80 °C for 2 h.
d
The iodination required 120 °C for 1 h.
e
2 was instead of 1.
f
1 mmol scale.
g
The oxidation required 1 d.
h
The iodination required 120 °C for 40 min.
i
6 mmol scale.

In order to demonstrate the utility of using this method in a synthetic strategy, I
attempted to iodinate methyl 2-(4-isobutylphenyl)propanoate, also known as ibuprofen.
Remarkably, this common material had not been selectively iodinated previously. It is
difficult to selectively iodinate the methyl ester of ibuprofen, as the 2 and 3 positon on
the aromatic ring are very electronically similar, and conventional electrophilic aromatic
substitution methods give a mixture of the two possible regioisomers, which are
especially difficult to separate using normal phase silica gel chromatography.
When the ibuprofen methyl ester was subjected to the standard conditions for
aryliodination using our method, a 9:1 mixture of the two possible regioisomeric
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diaryliodonium products were obtained (Scheme 1.14). Recrystallization gave the
desired, regioisomerically pure diaryliodonium salt intermediate product in good yield.
Dr. Hu then treated the diaryliodonium salt intermediate with 3 equivalents of sodium
iodide in acetonitrile at 80º C to form the corresponding iodide. Silica gel
chromatography (1:40 EtOAc:Hexanes) removed 5-iodoisophthalate to provide methyl 2(3-iodo-4-isobutylphenyl)propanoate in 65% overall yield.

Scheme 2.10 Iodination of ibuprofen methyl ester

Additionally, I attempted to iodinate bisphenol A dimethyl ether (BPAD) using
this new diaryliodonium salt approach. Initial experiments indicated that the strategy was
indeed viable, but reagents 1 and 2, when combined with TMSOTf as the activator,
proved to be overly electrophilic reagents, and reduction of the aryliodonium triflate was
a predominant side reaction. Dr. Hu, however, was able to use the aryliodination method
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to produce monoiodinated BPAD in good yield. He used a less aggressive aryliodonation
reagent, (4-methoxypheny)iodonium diacetate in place of 1 or 2, to form product in good
yield, as is shown in Scheme 1.14.

Scheme 2.11 Iodination of bisphenol A dimethyl ether (BPAD)

The iodination of BPAD is especially remarkable; every other common iodination
methods that we explored (NIS/TFA, Ag2SO4/I2, ICl) gave inseparable mixtures of
starting material and singly and multiply iodinated BPAD, even when a large excess of
BPAD was used. However, aryliodination was capable of forming a single
diaryliodonium salt, even when only a slight excess of BPAD was used. More surprising
is that this non-statistical preference for mono-substitution seems to be originate from a
through-bond electronic effect, since the T-shaped structure of the diaryliodonium salt
intermediate seems to preclude any through space aryl-aryl interaction of the 4methoxyphenyl ring with the unsubstituted ring of BPAD. The singly-substituted
diaryliodonium salt was readily separated from the unreacted BPAD by precipitation
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from ethyl acetate with hexanes, and iodination with excess KI was performed in
excellent yield.

2.3

CONCLUSIONS
In comparison to the Sandmeyer reaction, the preparation of aryl iodides using

aryliodination is functionally simpler and retains many of the advantages of the
Sandmeyer reaction. The formation of a polar, diaryliodonium salt intermediate that is
readily purified makes it quite simple to obtain good yields of single regioisomer aryl
iodides. In addition, the diaryliodonium salt intermediate possesses solubility
characteristics that make it possible to obtain good yields of iodinated arenes when the
reaction is carried out at low conversion. The aryliodination reagents’ reactivity may also
be tuned to match a range of electron-rich arenes, and the polarity of the aryliodoination
reagents can be modified to simplify product isolation by silica gel chromatography.
Using this method, iodoarenes that cannot normally be synthesized regioselectively by
electrophilic aromatic substitution may now be prepared. The two step process also
provides a method to isolate iodoarenes that would otherwise be extremely challenging
to separate from their unsubstituted parent compounds. Finally, these reagents are
characterized by a unique combination of reactivity and selectivity—they are
simultaneously more aggressive, regioselective, and chemoselective than standard
reagents for electrophilic aromatic iodination.
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2.4

EXPERIMENTAL

2.4.1 Materials
The chemicals were obtained from Aldrich Chemical Company and used as
received unless otherwise noted. Acetonitrile and acetonitrile-d3 (Cambridge Isotope
Laboratories) were dried over P2O5, distilled under reduced pressure into flame-dried
storage

tubes,

and

stored

under

dry

nitrogen.

TMSOTf

(trimethylsilyl

trifluoromethanesulfonate) was distilled prior to use. Selectfluor™ (1-chloromethyl-4fluoro-1,4-diazoniabicyclo[2.2.2]octane

bis(tetrafluoroborate))

(Oakwood

Chemical

Company) was dried in vacuo for 2 days at room temperature before use. All other
reagents were used as received. 1H NMR spectra were recorded on a Bruker Avance 400
MHz NMR spectrometer in the NMR Laboratory at the University of Nebraska-Lincoln.
2.4.2 Synthetic Procedures
Synthesis of 1-(diacetoxyiodo)-4-nitrobenzene, 1

To a 500 mL oven dried Schlenk flask in a nitrogen charged glovebox was added dry
acetonitrile (250 mL), 1-iodo-4-nitrobenzene (0.08 mol, 19.92 g), 1-(chloromethyl)-4fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.104 mol, 36.84 g) and
trimethylsilyl acetate (0.208 mol, 27.50 g). The reaction vessel was sealed, removed from
the glovebox, and heated at 50 °C for 24 hours with stirring. The reaction was allowed to
cool to room temperature and the acetonitrile was removed in vacuo. The orange solid
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was dissolved in dichloromethane (250 mL) washed with pH 5 acetate buffer (3 x 100
mL), dried over sodium sulfate, filtered, and the solvent was removed by rotary
evaporation. The orange solid was dissolved in dichloromethane (50 mL), and triturated
with a 10% diethyl ether/hexanes solution (250 mL) to give a pale yellow solid after
filtration. The solid was dried at room temperature in vacuo for 24 hours to obtain the
product in in 85% yield. 1H NMR (CD3CN, 400 MHz, 25 °C): δ 8.337 (q, J = 7.97 Hz,
4H), 1.949 (s, 6H).
Synthesis of dimethyl isophthalate

To a 500 mL round bottom flask was added methanol (250 mL) and isophthaloyl
dichloride (0.1 mol, 20.30 g). The reaction mixture was heated at reflux for 3 hours,
cooled to 0 °C, and filtered to afford dimethyl isophthalate as a white solid in 96% yield.
Synthesis of dimethyl 5-iodoisophthalate

To a 96% sulfuric acid solution was added iodine (0.056 mol, 7.11 g) and sodium
periodate (0.019 mol, 4.06 g). The reaction mixture was heated at 30 °C for 45 minutes,
at which point the reaction mixture became dark purple and dimethyl isophthalate (0.075
mol, 14.56 g) was added. After heating for another 12 hours at 30 °C, The reaction
mixture was poured over crushed ice, neutralized with sodium bicarbonate, filtered, and
rinsed with water. The purple solid was then dissolved in dichloromethane (100 mL),
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washed with a saturated sodium bicarbonate solution (1x 100 mL), water (3 x 100 mL),
and a saturated sodium bisulfite solution (3x 50 mL). The organic layer was dried over
sodium sulfate and concentrated in vacuo. The resulting white solid was then
recrystallized from boiling methanol to afford dimethyl 5-iodoisophthalate as a white
solid. The solid was dried at room temperature in vacuo for 24 hours to obtain the
product in in 73% yield. 1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.634 (s, 1H), 8.5505 (d, J
= 1.87 Hz, 2H), 3.957 (s, 6H).
Synthesis of 1-(diacetoxyiodo)-3,5-dicarboxymethylbenzene, 2

To a 500 mL oven dried Schlenk flask in a nitrogen charged glovebox was added dry
acetonitrile (250 mL), 5-iodoisophthalate (0.02 mol, 8.76 g), 1-(chloromethyl)-4-fluoro1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (0.026 mol, 9.21 g) and
trimethylsilyl acetate (0.052 mol, 6.88 g). The reaction vessel was sealed, removed from
the glovebox, and heated at 50 °C for 24 hours with stirring. The reaction was allowed to
cool to room temperature and the acetonitrile was removed in vacuo. The white solid was
dissolved in dichloromethane (250 mL) washed with pH = 5 acetate buffer (3 x 100 mL),
dried over sodium sulfate, and concentrated in vacuo. The orange solid was dissolved in
dichloromethane (50 mL), and triturated with a 10% diethyl ether/hexanes solution (250
mL) to give a white solid after filtration. The solid was dried at room temperature in
vacuo for 24 hours to obtain the product in 80% yield. 1H NMR (CDCl3, 400 MHz, 25
°C): δ 8.898 (d, J = 1.76 Hz, 2H), 8.866 (d, J = 1.79 Hz, 1H), 4.010 (s, 6H), 2.024 (s, 6H).
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Method A: Synthesis of iodoarenes using NIS and TFA (1 equivalent)
A solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was prepared. To
this mixture was added a solution of 1-iodo-2,5-pyrrolidinedione (N-iodosuccinimide)
and 2,2,2-trifluoroacetic acid in dry acetonitrile-d3 (1 mL, 1.1 M each in NIS and TFA).
The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of iodinated arenes
were determined by 1H NMR spectroscopy.
Method B: Synthesis of iodoarenes using NIS and TFA (2 equivalents)
A solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was prepared. To
this mixture was added a solution of N-iodosuccinimide and 2,2,2-trifluoroacetic acid in
dry acetonitrile-d3 (1 mL, 2.1 M each in NIS and TFA). The reaction vial was sealed and
heated at 50 °C for 12 hours. Yields of iodinated arenes were determined by 1H NMR
spectroscopy.
Method C: Synthesis of iodoarenes using Selectfluor™ and I2 (1 equivalent)
To a solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was added 1(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane

bis(tetrafluoroborate)

(0.06

mmol, 22 mg). To this mixture was added a solution of iodine in dry acetonitrile-d3 (1
mL, 0.6 M). The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of
iodinated arenes were determined by 1H NMR spectroscopy.
Method D: Synthesis of iodoarenes using Selectfluor™ and I2 (2 equivalents)
To a solution of arene (0.1 mmol) in dry acetonitrile-d3 (0.5 mL) was added 1(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane

bis(tetrafluoroborate)

(0.11

mmol, 39 mg). To this mixture was added an iodine solution in dry acetonitrile-d3 (1 mL,
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1.1 M). The reaction vial was sealed and heated at 50 °C for 12 hours. Yields of iodinated
arenes were determined by 1H NMR spectroscopy.
Method E: Synthesis of iodoarenes using 1-(diacetoxyiodo)-4-nitrobenzene (2
equivalents)
In a glovebox under nitrogen, trimethylsilyl trifluoromethanesulfonate (0.4 mmol,
89 mg) was added to a solution of 1-(diacetoxyiodo)-4-nitrobenzene (0.2 mmol, 73 mg)
in dry acetonitrile-d3 (1 mL). The solution was transferred to a 5 mm NMR tube, fitted
with a rubber septum, removed from the glovebox and sealed with paraffin film. To the
sealed NMR tube was added a solution of arene (0.1 mmol) dissolved in dry acetonitriled3 (0.5 mL). The reaction mixture was kept at room temperature for 3 hours, then
tetrabutylammonium iodide (0.15 mmol, 56 mg) was added and the reaction mixture was
diluted with 50 mL dichloromethane. The organic layer was washed with water (3 x 50
mL), dried over sodium sulfate, and concentrated in vacuo.
Method F: Synthesis of iodoarenes using 1-(diacetoxyiodo)-3,5dicarboxymethylbenzene (2 eqivalents)
In a glovebox under nitrogen, trimethylsilyl trifluoromethanesulfonate (0.4 mmol,
89

mg)

was

added

to

a

solution

of

dimethyl

1-(diacetoxyiodo)-3,5-

dicarboxymethylbenzene (0.2 mmol, 88 mg) in dry acetonitrile-d3 (1 mL). The solution
was transferred to a 5 mm NMR tube, fitted with a rubber septum, removed from the
glovebox and sealed with paraffin film. To the sealed NMR tube was added a solution of
arene (0.1 mmol) dissolved in dry acetonitrile-d3 (0.5 mL). The reaction mixture was kept
at room temperature for 3 hours, then tetrabutylammonium iodide (0.15 mmol, 56 mg)
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was added and the reaction mixture was diluted with 20 mL dichloromethane. The
organic layer was washed with water (3 x 10 mL), dried over sodium sulfate, and
concentrated in vacuo.
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4.1

APPENDIX A: NMR Data

Figure S1. 1H NMR spectrum of 1 in CD3CN.
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Figure S2. 1H NMR spectrum of 5-iododimethylisophthalate in CDCl3
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Figure S3. 1H NMR spectrum of 2 in CD3CN.
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3

Figure S4. 1H NMR spectrum of 3 in CD3CN.
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3

Figure S5. 1H NMR spectrum of the iodination of 3 by Method A in CD3CN.
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3

Figure S6. 1H NMR spectrum of the iodination of 3 by Method B in CD3CN.
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3

Figure S7. 1H NMR spectrum of the iodination of 3 by Method C in CD3CN.
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3

Figure S8. 1H NMR spectrum of the iodination of 3 by Method D in CD3CN.
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3

Figure S9. 1H NMR spectrum of the iodination of 3 by Method F in CD3CN.
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4

Figure S11. 1H NMR spectrum of 4 in CD3CN.
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4

Figure S12. 1H NMR spectrum of the iodination of 4 by Method A in CD3CN.
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4

Figure S13. 1H NMR spectrum of the iodination of 4 by Method B in CD3CN.

68

4

Figure S14. 1H NMR spectrum of the iodination of 4 by Method C in CD3CN.
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4

Figure S15. 1H NMR spectrum of the iodination of 4 by Method D in CD3CN.
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4

Figure S16. 1H NMR spectrum of the iodination of 4 by Method F in CD3CN.
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5

Figure S17. 1H NMR spectrum of 5 in CD3CN.
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5

Figure S18. 1H NMR spectrum of the iodination of 5 by Method A in CD3CN.

73

5

Figure S19. 1H NMR spectrum of the iodination of 5 by Method B in CD3CN.
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5

Figure S20. 1H NMR spectrum of the iodination of 5 by Method C in CD3CN.
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5

Figure S21. 1H NMR spectrum of the iodination of 5 by Method D in CD3CN.
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5

Figure S22. 1H NMR spectrum of the iodination of 5 by Method f in CD3CN.
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6

Figure S23. 1H NMR spectrum of 6 in CD3CN.
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6

Figure S24. 1H NMR spectrum of the iodination of 6 by Method A in CD3CN.
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6

Figure S25. 1H NMR spectrum of the iodination of 6 by Method B in CD3CN.
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6

Figure S26. 1H NMR spectrum of the iodination of 6 by Method C in CD3CN.
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6

Figure S27. 1H NMR spectrum of the iodination of 6 by Method D in CD3CN.
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6

Figure S28. 1H NMR spectrum of the iodination of 6 by Method E in CD3CN.
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Figure S29. 1H NMR spectrum of 7 in CD3CN.
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Figure S31. 1H NMR spectrum of the iodination of 7 by Method B in CD3CN.
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Figure S32. 1H NMR spectrum of the iodination of 7 by Method C in CD3CN.
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Figure S33. 1H NMR spectrum of the iodination of 7 by Method D in CD3CN.
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Figure S34. 1H NMR spectrum of the iodination of 7 by Method E in CD3CN.
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Figure S35. 1H NMR spectrum of 8 in CD3CN.
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Figure S36. 1H NMR spectrum of the iodination of 8 by Method A in CD3CN.
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Figure S37. 1H NMR spectrum of the iodination of 8 by Method B in CD3CN.
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Figure S38. 1H NMR spectrum of the iodination of 8 by Method C in CD3CN.
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Figure S39. 1H NMR spectrum of the iodination of 8 by Method D in CD3CN.
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Figure S40. 1H NMR spectrum of the iodination of 8 by Method E in CD3CN.
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Figure S53. 1H NMR spectrum of 11 in CD3CN.
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Figure S54. 1H NMR spectrum of the iodination of 11 by Method A in CD3CN.
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Figure S55. 1H NMR spectrum of the iodination of 11 by Method B in CD3CN.
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Figure S56. 1H NMR spectrum of the iodination of 11 by Method C in CD3CN.
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Figure S57. 1H NMR spectrum of the iodination of 11 by Method D in CD3CN.
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Figure S58. 1H NMR spectrum of the iodination of 11 by Method E in CD3CN.
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Figure S59. 1H NMR spectrum of 12 in CD3CN.
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Figure S60. 1H NMR spectrum of the iodination of 12 by Method A in CD3CN.
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Figure S61. 1H NMR spectrum of the iodination of 12 by Method B in CD3CN.
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Figure S62. 1H NMR spectrum of the iodination of 12 by Method C in CD3CN.

104

Figure S63. 1H NMR spectrum of the iodination of 12 by Method D in CD3CN.
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Figure S64. 1H NMR spectrum of the iodination of 12 by Method E in CD3CN.
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Figure S65. 1H NMR spectrum of 13 in CD3CN.
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Figure S66. 1H NMR spectrum of the iodination of 13 by Method A in CD3CN.
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Figure S67. 1H NMR spectrum of the iodination of 13 by Method B in CD3CN.
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Figure S68. 1H NMR spectrum of the iodination of 13 by Method C in CD3CN.

110

Figure S69. 1H NMR spectrum of the iodination of 13 by Method D in CD3CN.
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Figure S70. 1H NMR spectrum of the iodination of 13 by Method E in CD3CN.
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15

Figure S77. 1H NMR spectrum of 15 in CD3CN.
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15

Figure S78. 1H NMR spectrum of the iodination of 15 by Method A in CD3CN.
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15

Figure S79. 1H NMR spectrum of the iodination of 15 by Method B in CD3CN.
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15

Figure S80. 1H NMR spectrum of the iodination of 15 by Method C in CD3CN.
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15

Figure S81. 1H NMR spectrum of the iodination of 15 by Method D in CD3CN.

117

15

Figure S82. 1H NMR spectrum of the iodination of 15 by Method F in CD3CN.
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16

Figure S83. 1H NMR spectrum of 16 in CD3CN.
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16

Figure S84. 1H NMR spectrum of the iodination of 16 by Method A in CD3CN.
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16

Figure S85. 1H NMR spectrum of the iodination of 16 by Method B in CD3CN.
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16

Figure S86. 1H NMR spectrum of the iodination of 16 by Method C in CD3CN.
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16

Figure S87. 1H NMR spectrum of the iodination of 16 by Method D in CD3CN.
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16

Figure S88. 1H NMR spectrum of the iodination of 16 by Method F in CD3CN.
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Figure S89. 1H NMR spectrum of 17 in CD3CN.
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Figure S90. 1H NMR spectrum of the iodination of 17 by Method A in CD3CN.

126

Figure S91. 1H NMR spectrum of the iodination of 17 by Method B in CD3CN.
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Figure S92. 1H NMR spectrum of the iodination of 17 by Method C in CD3CN.
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Figure S93. 1H NMR spectrum of the iodination of 17 by Method D in CD3CN.
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Figure S94. 1H NMR spectrum of the iodination of 17 by Method E in CD3CN.
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Figure S107. 1H NMR spectrum of 20 in CD3CN.

131

Figure S108. 1H NMR spectrum of the iodination of 20 by Method A in CD3CN.
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Figure S109. 1H NMR spectrum of the iodination of 20 by Method B in CD3CN.
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Figure S110. 1H NMR spectrum of the iodination of 20 by Method C in CD3CN.
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Figure S111. 1H NMR spectrum of the iodination of 20 by Method D in CD3CN.
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Figure S112. 1H NMR spectrum of the iodination of 20 by Method E in CD3CN.
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